Humanigen Inc - Company Profile
Powered by 
All the data and insights you need on Humanigen Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Humanigen Inc Strategy Report
- Understand Humanigen Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Humanigen Inc (Humanigen) is a biopharmaceutical company that develops proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company provides Ifabotuzumab(anti-EphA3) and Lenzilumab(anti-GM-CSF) recombinant monoclonal antibodies, used for the treatment of solid tumors and their microenvironment, and certain hematologic malignancies such as chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia. It has developed the recombinant monoclonal antibodies using its proprietary drug discovery technology called Humaneered. Humanigen also provides data on on pharmacokinetics and pharmacodynamics including correlative biomarkers and mutational analysis for conducting studies in and juvenile myelomonocytic leukemia. The company has operations in Australia and the UK. Humanigen is headquartered in Burlingame, California, the US.
Headquarters
United States of America
Address
830 Morris Turnpike, 4th Floor, Short Hills, New Jersey, 07078
Website
www.humanigen.com
Telephone
1 973 2003100
No of Employees
6
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
HGENQ (OTC)
Revenue (2021)
$2.5M
-30.1%
(2021 vs 2020)
EPS
XYZ
Net Income (2021)
XYZ
70.1%
(2021 vs 2020)
Market Cap*
$10,000
Net Profit Margin (2021)
XYZ
57.3%
(2021 vs 2020)
* As of and is in US$
Humanigen Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Ifabotuzumab(anti-EphA3) - for the Treatment of Solid Tumor Cells | Humaneered |
| Lenzilumab(anti-GM-CSF) - for the Treatment of Chronic Myelomonocytic Leukemia (CMML), | |
| Benznidazole - for the Treatment of Chagas Disease | |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | Humanigen Inc | Arrowhead Pharmaceuticals Inc | Dicerna Pharmaceuticals Inc | HemaCare Corp | InVivo Therapeutics Holdings Corp |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Short Hills | Pasadena | Lexington | Northridge | Cambridge |
| State/Province | New Jersey | California | Massachusetts | California | Massachusetts |
| No. of Employees | 6 | 525 | - | - | 6 |
| Entity Type | Public | Public | Private | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Cameron Durrant | Chairman; Chief Executive Officer | Executive Board | 2016 | 62 |
| Dale Chappell | Director; Chief Scientific Officer | Executive Board | 2021 | 52 |
| Bob Atwill | Head - Asia-Pacific Region and Business Development | Senior Management | - | - |
| Cheryl Buxton | Director | Non Executive Board | - | - |
| Ronald Barliant | Director | Non Executive Board | 2016 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer